Opthea Ltd Announces AGM Results & A$15.9M Tax Incentive
Ticker: OPTEY · Form: 6-K · Filed: Nov 15, 2024 · CIK: 1815620
Sentiment: neutral
Topics: agm, board-appointment, r&d-tax-incentive
TL;DR
Opthea snagged A$15.9M R&D cash, appointed a new board member, and held its AGM.
AI Summary
Opthea Limited filed a Form 6-K on November 15, 2024, detailing several announcements. Key among these are the Chairman's Address at the Annual General Meeting (AGM), the appointment of Kathy Connell to the Board of Directors, the results of the 2024 AGM, and the receipt of an A$15.9 million R&D Tax Incentive. The company is incorporated in Australia and its fiscal year ends on June 30.
Why It Matters
The R&D tax incentive provides significant funding for Opthea's research and development efforts, potentially accelerating its drug development pipeline. The board changes could signal shifts in strategic direction or governance.
Risk Assessment
Risk Level: medium — The filing indicates a company in the biotechnology sector, which inherently carries higher risks due to the nature of drug development and regulatory hurdles, though no specific negative events are detailed.
Key Numbers
- A$15.9 Million — R&D Tax Incentive (Funding for research and development)
Key Players & Entities
- Opthea Limited (company) — Registrant
- Kathy Connell (person) — Appointed to Board of Directors
- A$15.9 Million (dollar_amount) — R&D Tax Incentive received
FAQ
What was the primary purpose of the Chairman's Address at the AGM?
The filing does not provide the specific content of the Chairman's Address, only that it was presented at the Annual General Meeting.
When was Kathy Connell appointed to the Board of Directors?
The filing lists a press release regarding the appointment of Kathy Connell to the Board of Directors as Exhibit 99.2, but does not state the exact date of appointment within the provided text.
What were the key outcomes of the 2024 AGM?
Exhibit 99.3 is a press release detailing the 2024 AGM Results, but the specific outcomes are not detailed in the provided text.
What is the significance of the A$15.9 Million R&D Tax Incentive for Opthea?
The A$15.9 Million R&D Tax Incentive is intended to support Opthea's research and development activities, as indicated by its inclusion as Exhibit 99.4.
Does Opthea file annual reports under Form 20-F or Form 40-F?
Opthea indicates that it files annual reports under Form 20-F.
Filing Stats: 175 words · 1 min read · ~1 pages · Grade level 10.6 · Accepted 2024-11-15 06:02:36
Key Financial Figures
- $15.9 Million — 99.4 Press Release - Opthea Receives A$15.9 Million R&D Tax Incentive P SIGNATURES Pu
Filing Documents
- opt_-_opthea_agm_and_boa.htm (6-K) — 25KB
- opt-ex99_1.htm (EX-99.1) — 28KB
- opt-ex99_2.htm (EX-99.2) — 22KB
- opt-ex99_3.htm (EX-99.3) — 84KB
- opt-ex99_4.htm (EX-99.4) — 18KB
- img260626642_0.jpg (GRAPHIC) — 61KB
- img260626642_1.jpg (GRAPHIC) — 61KB
- 0000950170-24-127381.txt ( ) — 346KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized. OPTHEA LIMITED (Registrant) By: /s/ Frederic Guerard Name: Frederic Guerard Title: Chief Executive Officer Date: 11/15/2024